Phaseline

Companies › MediciNova

MediciNova: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MN-001 (tipelukast)
Cysteinyl leukotriene receptor antagonist
CYSLTR1Phase 2Diabetes Mellitus, Type 2Dec 2026
Ibudilast (MN-166)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Amyotrophic Lateral SclerosisApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05464784MN-001 (tipelukast)Phase 2Diabetes Mellitus, Type 2Metabolic and endocrineDec 2026
NCT04057898Ibudilast (MN-166)Phase 2Amyotrophic Lateral SclerosisNeurologyApr 2027

From the company's SEC filings

Cash of $25m on 2026-06-30; operating cash outflow about $11m a year; runway about 28 months at that burn, to Oct 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

CYSLTR1 (1) PDE4A (1) PDE4D (1) PDE4B (1) PDE4C (1) PDE3A (1)

Companies with the same targets

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Merck & Co. (MSD) Amgen Ganzhou Hemay Pharmaceutical Arcutis Biotherapeutics Integrative Skin Science and Research Shionogi Tetra Discovery Partners Tenax Therapeutics

Companies built like this

Corxel Pharmaceuticals Shenzhen Wingor Biotechnology NeuroBiogen Urovant Sciences SAb Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.